Table 4

Results of the main and sensitivity analyses (based on 5,000 bootstrap simulations)

Incremental costs, €
(95% CI)
Incremental effects
(95% CI)
Mean
ICER/ICUR (95% CI)
Distribution over the incremental cost-effectiveness plane
NENW SESW
Analysis ACTonPainguided vs CG
 Cost-effectiveness analysis
(treatment response)
6
(−916 to 953)
0.14
(0.08 to 0.2)
45
(−6,671 to 8,260)
50%50%
 Cost-utility analysis
(QALYs based on AQoL-8D)
6
(−916 to 953)
0.01
(0.005 to 0.015)
604
(−92,924 to 114,325)
50%50%
 Sensitivity analysis
(QALYs based on EQ5D-3L)
6
(−916 to 953)
0.014
(0.004 to 0.024)
438 (−69,407 to 122,314)50%50%
Analysis ACTonPainunguided vs CG
 Cost-effectiveness analysis
(treatment response)
−352
(−1,968 to 1,272)
0.12
(0.006 to 0.232)
ACTonPainunguided dominates CG32%1%66%1%
 Cost-utility analysis
(QALYs based on AQoL-8D)
−352
(−1,968 to 1,272)
0.013
(0.002 to 0.024)
ACTonPainunguided dominates CG32%1%66%1%
 Sensitivity analysis
(QALYs based on EQ5D-3L)
−352
(−1,968 to 1,272)
0.017 (−0.005 to 0.04)ACTonPainunguided dominates CG30%4%64%3%
Analysis ACTonPainguided vs ACTonPainunguided
 Cost-effectiveness analysis
(treatment response)
388
(−1,416 to 2,185)
0.164
(0.034 to 0.29)
2,374 (−11,097 to 25,276)65%35%
 Cost-utility analysis
(QALYs based on AQoL-8D)
388
(−1,416 to 2,185)
0.008
(−0.003 to 0.019)
45,993*60%5%33%2%
 Sensitivity analysis
(QALYs based on EQ5D-3L)
388
(−1,416 to 2,158)
0.01 (−0.01 to 0.031)37,327*53%12%31%4%
  • CG, waitlist control group; ICER, incremental cost-effectiveness ratio; ICUR, incremental cost-utility ratio; MPI, Pain Interference Scale of the Multidimensional Pain Inventory; NE, northeast quadrant; NW, northwest quadrant; PGIC, Patient Global Impression of Change scale; ; SE, southeast quadrant; SW, southwest quadrant.

  • *A dependably accurate 95% CI for this distribution cannot be defined because there is no line through the origin that excludes α/2 of the distribution.73